{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nitrogen+%28placebo%29&page=2",
    "query": {
      "intervention": "Nitrogen (placebo)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 266,
    "total_pages": 27,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nitrogen+%28placebo%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nitrogen+%28placebo%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T13:37:51.854Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00104299",
      "title": "Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Vasculitis",
        "Wegener's Granulomatosis",
        "Microscopic Polyangiitis"
      ],
      "interventions": [
        {
          "name": "Rituximab plus cyclophosphamide placebo (rituximab group)",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide plus rituximab placebo (control group)",
          "type": "DRUG"
        },
        {
          "name": "Azathioprine",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone (or other glucocorticoid)",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 197,
      "start_date": "2005-01",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-10-04T13:37:51.854Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00104299"
    },
    {
      "nct_id": "NCT00722098",
      "title": "Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Melanoma Stage IV"
      ],
      "interventions": [
        {
          "name": "DC Vaccine & Cyclophosphamide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DC Vaccine & Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 9,
      "start_date": "2008-06",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2013-07-08",
      "last_synced_at": "2026-10-04T13:37:51.854Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00722098"
    },
    {
      "nct_id": "NCT01728220",
      "title": "Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Hypertension",
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Inhaled NO delivered via INOpulse DS-C Device",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo delivered via INOpulse DS-C Device",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Bellerophon Pulse Technologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 159,
      "start_date": "2012-12",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2023-02-27",
      "last_synced_at": "2026-10-04T13:37:51.854Z",
      "location_count": 43,
      "location_summary": "Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 35 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01728220"
    },
    {
      "nct_id": "NCT03869736",
      "title": "Nitrous Oxide for the Treatment of Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depression",
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Nitrous Oxide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayside Health",
      "sponsor_class": "OTHER_GOV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2019-01-22",
      "completion_date": "2023-12-10",
      "has_results": false,
      "last_update_posted_date": "2024-12-16",
      "last_synced_at": "2026-10-04T13:37:51.854Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03869736"
    },
    {
      "nct_id": "NCT01220687",
      "title": "Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Respiratory Distress Syndrome in Premature Infants",
        "Very Low Birth Weight Baby"
      ],
      "interventions": [
        {
          "name": "iNO",
          "type": "DRUG"
        },
        {
          "name": "Nitrogen",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Minute",
        "maximum_age": "2 Minutes",
        "sex": "ALL",
        "summary": "1 Minute to 2 Minutes"
      },
      "enrollment_count": 33,
      "start_date": "2011-04",
      "completion_date": "2017-05-01",
      "has_results": true,
      "last_update_posted_date": "2020-08-19",
      "last_synced_at": "2026-10-04T13:37:51.854Z",
      "location_count": 2,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01220687"
    },
    {
      "nct_id": "NCT01064479",
      "title": "Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Squamous Cell Carcinoma of the Hypopharynx",
        "Metastatic Squamous Cell Carcinoma of the Larynx",
        "Metastatic Squamous Cell Carcinoma of the Oral Cavity",
        "Metastatic Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Hypopharyngeal Squamous Cell Carcinoma",
        "Recurrent Laryngeal Squamous Cell Carcinoma",
        "Recurrent Oral Cavity Squamous Cell Carcinoma",
        "Recurrent Oropharyngeal Squamous Cell Carcinoma",
        "Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 123,
      "start_date": "2010-02-05",
      "completion_date": "2020-11-03",
      "has_results": true,
      "last_update_posted_date": "2024-07-16",
      "last_synced_at": "2026-10-04T13:37:51.854Z",
      "location_count": 5,
      "location_summary": "Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Nassau Bay",
          "state": "Texas"
        },
        {
          "city": "Sugar Land",
          "state": "Texas"
        },
        {
          "city": "The Woodlands",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01064479"
    },
    {
      "nct_id": "NCT06623422",
      "title": "A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Intismeran autogene",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 680,
      "start_date": "2024-10-21",
      "completion_date": "2038-01-26",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-04T13:37:51.854Z",
      "location_count": 52,
      "location_summary": "Gilbert, Arizona • Tucson, Arizona • Fullerton, California + 40 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06623422"
    },
    {
      "nct_id": "NCT04529772",
      "title": "A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "acalabrutinib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acerta Pharma BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 611,
      "start_date": "2020-10-08",
      "completion_date": "2027-02-22",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-10-04T13:37:51.854Z",
      "location_count": 32,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 28 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Norwich",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04529772"
    },
    {
      "nct_id": "NCT02576275",
      "title": "A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Indolent Non-Hodgkin's Lymphoma",
        "Follicular Lymphoma",
        "Small Lymphocytic Lymphoma",
        "Marginal Zone Lymphoma"
      ],
      "interventions": [
        {
          "name": "Duvelisib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SecuraBio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-12",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2021-03-17",
      "last_synced_at": "2026-10-04T13:37:51.854Z",
      "location_count": 7,
      "location_summary": "Plainville, Connecticut • Plantation, Florida • Thomasville, Georgia + 4 more",
      "locations": [
        {
          "city": "Plainville",
          "state": "Connecticut"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Thomasville",
          "state": "Georgia"
        },
        {
          "city": "East Setauket",
          "state": "New York"
        },
        {
          "city": "Cookeville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02576275"
    },
    {
      "nct_id": "NCT02994433",
      "title": "NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Depressive Disorder, Major",
        "Depressive Disorder, Treatment-Resistant"
      ],
      "interventions": [
        {
          "name": "Nitrous Oxide",
          "type": "DRUG"
        },
        {
          "name": "Placebo gas",
          "type": "DRUG"
        },
        {
          "name": "MRI",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2017-01-27",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-10-04T13:37:51.854Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02994433"
    }
  ]
}